rs17036314 — PPARG

Intronic PPARG variant — carriers of the C allele have elevated fasting glucose and higher risk of converting from impaired glucose tolerance to type 2 diabetes; the effect is substantially reduced by increased aerobic physical activity

See your personal result for PPARG

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

PPARG rs17036314 — Exercise Unlocks Your Genetic Risk

The PPARG gene encodes Peroxisome Proliferator-Activated Receptor Gamma11 Peroxisome Proliferator-Activated Receptor Gamma
PPARγ is a nuclear transcription factor that acts as the master regulator of fat cell formation and insulin sensitization, the protein that coordinates adipocyte differentiation and insulin sensitization. It is also the molecular target of thiazolidinedione22 Thiazolidinediones (e.g., pioglitazone, rosiglitazone) are diabetes drugs that bind and activate PPARγ, improving insulin sensitivity drugs used in treating type 2 diabetes. rs17036314 is an intronic variant in PPARG — it does not change the protein sequence itself but sits within a regulatory region of the gene that influences transcriptional output in metabolically active tissues.

The Mechanism

As an intronic variant, rs17036314 likely affects how efficiently or in what pattern PPARG is expressed in insulin-responsive tissues such as skeletal muscle and adipose tissue. The C allele tags a haplotype block in PPARG intron 2 that is associated with higher fasting plasma glucose at baseline and greater risk of progressing from impaired glucose tolerance33 impaired glucose tolerance
A pre-diabetic state: fasting glucose 100-125 mg/dL or 2-hour post-load glucose 140-199 mg/dL to frank type 2 diabetes. Critically, the risk effect is not fixed: increased aerobic physical activity appears to override the genetic predisposition, restoring normal glucose regulation trajectories in C carriers who become more active.

The Evidence

The primary study is the Finnish Diabetes Prevention Study (DPS), a multi-center randomized trial in which 479 overweight individuals with impaired glucose tolerance were followed for an average of 4.2 years with annual physical activity assessment. Lindi et al. 200744 Lindi et al. 2007
Lindi et al. SNPs in PPARG associate with type 2 diabetes and interact with physical activity. Med Sci Sports Exerc 2008;40(1):25-33 found that C allele carriers had significantly higher fasting glucose at baseline and that the rare C allele predicted conversion to T2D (P = 0.038); uniquely among the seven PPARG SNPs studied, this association remained after adjustment for baseline fasting glucose (P = 0.030). Most importantly, the interaction test between change in physical activity and rs17036314 was highly significant (P = 0.002): participants who substantially increased their activity level showed no excess T2D risk from the C allele, while those who remained sedentary retained the elevated risk.

Although the effect estimate for this intronic variant is modest in cross-sectional GWAS settings, the gene-environment interaction is one of the strongest replicated exercise-by-genotype interactions in the T2D prevention literature. The variant has also been genotyped in a Sudanese candidate-gene study of T2D loci (Mtiraoui et al. 201655 Mtiraoui et al. 2016
Mtiraoui et al. Candidate gene analysis supports a role for polymorphisms at TCF7L2 as risk factors for type 2 diabetes in Sudan. J Diabetes Res 2016), supporting relevance across diverse populations.

Practical Actions

For C allele carriers, the evidence strongly supports aerobic exercise as a primary metabolic intervention — not just for general fitness, but specifically to override the genetic risk this variant confers. The DPS data indicate that increasing total weekly physical activity volume is the lever: participants who moved from low activity to above-median activity abolished the C-allele risk. Monitoring fasting glucose and HbA1c provides objective feedback on whether the intervention is working.

Interactions

rs17036314 shares a gene with rs1801282 (PPARG Pro12Ala), the most studied PPARG variant. In the Finnish DPS, both variants predicted T2D conversion, and both interacted with physical activity. They likely tag different functional haplotypes within PPARG and can compound. The PPARD variant rs2016520 and PPARGC1A rs8192678 (Gly482Ser) operate in the same transcriptional pathway; one study found that combinations of these PPAR-family variants predicted IGT-to-T2D conversion better than any single variant alone.

Genotype Interpretations

What each possible genotype means for this variant.

GG Normal

Common PPARG variant — standard metabolic risk profile

The G/G genotype at rs17036314 represents the ancestral state of the PPARG intron 2 haplotype. Carriers of this genotype did not show elevated baseline fasting glucose or increased T2D conversion risk in the Finnish Diabetes Prevention Study. Your metabolic risk from this particular PPARG variant is within the normal population range.

CG Heterozygous Risk Intermediate

One C allele — mildly elevated T2D risk, responsive to aerobic exercise

Heterozygous C/G carriers have one copy of the PPARG intron 2 C haplotype. In the DPS study (Lindi et al. 2008, PMID 18091023), the rare C allele predicted T2D conversion both unadjusted (P = 0.038) and after adjustment for baseline fasting glucose (P = 0.030). The interaction between change in total physical activity and rs17036314 was significant at P = 0.002, making this one of the more robustly demonstrated exercise-modifiable genetic risk variants in metabolic research. The biological interpretation is that increased PPARG pathway activity in skeletal muscle — induced by endurance exercise — compensates for any dysregulation tagged by the C haplotype.

CC Homozygous Risk High Risk

Two C alleles — higher T2D risk, strongly exercise-modifiable

The C/C genotype places both copies of PPARG intron 2 in the risk haplotype. In the additive model used in the DPS (Lindi et al. 2008, PMID 18091023), the rs17036314 C allele predicted T2D conversion independently of baseline fasting glucose — a finding that suggests the variant influences metabolic trajectories through pathways beyond simple glucose regulation at a single time point. The remarkable aspect of this variant is the magnitude of the gene-exercise interaction (P = 0.002): it is one of the largest exercise-responsive effect modifications seen for a diabetes risk variant, suggesting that for C/C carriers, physical activity is not just a general health recommendation but a genotype-targeted metabolic intervention.